Butterfly Network vs Causaly

Butterfly Network has a disclosed valuation of $1.5B, while Causaly's valuation is not publicly available, making a direct size comparison difficult. Butterfly Network employs 500-1000 people.

Butterfly Network has raised $700M in disclosed funding across 0 known rounds. Causaly's funding history is not publicly available.

Butterfly Network holds the higher Awaira Score at 85/100, compared to Causaly's 45/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 40-point gap that reflects meaningful differences in scale or traction.

Butterfly Network was founded by John Martin in 2011. Causaly was founded by Elias Iosif in 2018. Visit each company's profile on Awaira for a full founder biography.

Butterfly Network: Butterfly Network produces the Butterfly iQ, a handheld ultrasound device powered by a proprietary semiconductor chip that replaces traditional piezoelectric transducer arrays with a single silicon chip capable of whole-body imaging. The AI software layer provides real-time image interpretation guidance, enabling clinicians with limited ultrasound training to perform diagnostic scans at the bedside.\n\nThe company is publicly traded on the NYSE under the ticker BFLY and raised over 700 million USD prior to and through its public listing. Butterfly has deployed devices across hospitals, emergency rooms, and point-of-care settings in over 50 countries, with particular penetration in resource-limited healthcare settings where traditional ultrasound equipment is prohibitively expensive or unavailable.\n\nPortable AI-assisted diagnostic imaging represents a structural shift in how and where medical imaging is performed. Butterfly Network has created a defensible position through its proprietary chip architecture, which competitors cannot easily replicate, and through its growing library of AI-assisted clinical guidance tools. The transition from hospital-based imaging to point-of-care diagnostics powered by AI guidance is a multi-decade trend that positions Butterfly at the center of a fundamental change in diagnostic medicine. Causaly: Causaly built a biomedical AI platform that extracts and maps causal relationships from scientific literature at scale, allowing pharmaceutical researchers and scientists to query cause-and-effect relationships across millions of published papers and clinical documents. The platform used a specialised natural language processing system trained to identify causal assertions in biomedical text, producing a structured knowledge graph of disease mechanisms, drug targets, and biological pathways.\n\nThe company was founded in London in 2018 and was acquired by Elsevier, the academic publishing giant, in 2022. The acquisition gave Elsevier an AI layer to sit atop its vast corpus of scientific publications, enabling researchers using ScienceDirect and other Elsevier products to query causal biological knowledge rather than simply searching for documents. Prior to acquisition, Causaly had built a client base among pharmaceutical R&D teams seeking to accelerate literature review and hypothesis generation.\n\nCausaly represented a niche but strategically important segment of the biomedical AI market: causal reasoning and knowledge graph construction. Its acquisition by Elsevier followed a broader trend of academic publishers acquiring AI startups to enhance their platforms, similar to Wiley acquiring Atypon and Springer Nature building AI discovery tools. The company is now integrated into Elsevier Research Intelligence, extending causal AI capabilities to Elsevier institutional subscribers worldwide.

Butterfly Network was founded first in 2011, giving it 7 years of additional market experience. Causaly was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Butterfly Network has approximately 500-1000 employees, while Causaly has approximately 1-50. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Butterfly Network and Causaly are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.